The impact of tumor size change after target therapy on survival: analysis of patients enrolled onto three clinical trials of advanced NSCLC from one institution
Jianwei Zhang,* Yan Huang,* Xiaoling Li, Ying Guo, Yuanyuan Zhao, Cong Xue, Zhihuang Hu, Li Zhang, Hongyun ZhaoState Key Laboratory of Oncology in South China, Sun Yat-Sen University Cancer Center, Guangzhou, China*These authors contributed equally to this work and share the first authorshipPurpose:...
Main Authors: | Zhang J, Huang Y, Li X, Guo Y, Zhao Y, Xue C, Hu Z, Zhang L, Zhao H |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2012-11-01
|
Series: | OncoTargets and Therapy |
Online Access: | http://www.dovepress.com/the-impact-of-tumor-size-change-after-target-therapy-on-survival-analy-a11526 |
Similar Items
-
Combination of EGFR-TKIs with chemotherapy versus chemotherapy or EGFR-TKIs alone in advanced NSCLC patients with EGFR mutation
by: Wen M, et al.
Published: (2018-11-01) -
A Review About Pembrolizumab in First-Line Treatment of Advanced NSCLC: Focus on KEYNOTE Studies
by: Qu J, et al.
Published: (2020-07-01) -
Second-Line Chemotherapy in Advanced Non-Small Cell Lung Cancer (NSCLC): Single Institution Experience
by: Hanaa Attia, et al.
Published: (2017-06-01) -
The Efficacy and Safety of Apatinib in Advanced Synovial Sarcoma: A Case Series of Twenty-One Patients in One Single Institution
by: Wang Y, et al.
Published: (2020-07-01) -
The Efficacy and Safety of Apatinib in Advanced Synovial Sarcoma: A Case Series of Twenty-One Patients in One Single Institution [Corrigendum]
by: Wang Y, et al.
Published: (2020-09-01)